Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY12.32 CNY
Change Today -0.21 / -1.68%
Volume 25.3M
600267 On Other Exchanges
As of 3:05 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

zhejiang hisun pharmaceuti-a (600267) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/15/15 - CNY27.93
52 Week Low
09/16/15 - CNY10.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZHEJIANG HISUN PHARMACEUTI-A (600267)

Related News

No related news articles were found.

zhejiang hisun pharmaceuti-a (600267) Related Businessweek News

No Related Businessweek News Found

zhejiang hisun pharmaceuti-a (600267) Details

Zhejiang Hisun Pharmaceutical Co. Ltd. manufactures and distributes pharmaceuticals. The company’s products include antineoplastic, cardiovascular, anti-infection, endocrine control, anti-parasite, and anti-infective drugs, as well as animal remedies. The company distributes its products under the HISUN brand in approximately 70 countries and regions. The company was founded in 1956 and is headquartered in Taizhou, China.

Founded in 1956

zhejiang hisun pharmaceuti-a (600267) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zhejiang hisun pharmaceuti-a (600267) Key Developments

Zhejiang Hisun Pharmaceutical Co., Ltd. Receives Warning Letter from the FDA for Bulk Drug Imports by Taizhou Plant

Zhejiang Hisun Pharmaceutical Co., Ltd. declared to receive warning letter from the FDA for bulk drug imports by Taizhou plant after investigation from March 2 to 7. The Taizhou plant has 29 kinds of bulk drugs admitted to enter US. But, from the day receiving the warning letter to confirmation from the FDA, 15 of them will be forbidden to enter US shortly while 14 are still allowed to be sold in the nation.

Zhejiang Hisun Pharmaceutical Co., Ltd. Announces Earnings Results for the First Half of 2015

Zhejiang Hisun Pharmaceutical Co., Ltd. announced earnings results for the first half of 2015. For the first half, the company reported, basic earnings per share of CNY 0.038, weighted average return on net assets of 0.522%.

Zhejiang Hisun Pharmaceutical Co., Ltd., Board Meeting, Aug 14, 2015

Zhejiang Hisun Pharmaceutical Co., Ltd., Board Meeting, Aug 14, 2015. Agenda: To discuss and approve issues including the semi-annual report of 2015; to consider the proposal of deposit and actual usage of raised funds in the first half of 2015; and to consider the proposal of providing guarantee for bank loan of wholly-owned subsidiary.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600267:CH CNY12.32 CNY -0.21

600267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600267.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600267 Industry Range
Price/Earnings 59.9x
Price/Sales 1.6x
Price/Book 1.5x
Price/Cash Flow 61.3x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZHEJIANG HISUN PHARMACEUTI-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at